Challenges and Opportunities for Integrating In Silico Models and Adverse Outcomes Pathways to Set and Relate New Biomarkers

Abstract

The Adverse Outcome Pathway (AOP) framework has been considered the most innovative tool to collect, organize, and evaluate relevant information on the toxicological effects of chemicals, facilitating the establishment of links between molecular events and adverse outcomes at the critical level of biological organization. Considering the combination of the high volume of toxicological and ecotoxicological data produced and the application of artificial intelligence algorithms from the last few years, not only can higher mechanistic interpretability be reached with new in silico models, but also a potential increase in predictivity in hazard assessments and the identification of new potential biomarkers can be achieved. The current paper aims to discuss some potential challenges and ways of integrating in silico models and AOPs to predict toxicological effects and to set and relate new biomarkers for defined purposes. With the use of the AOP framework to organize the ecotoxicological, toxicological, and structural data generated from in chemico, in vitro, ex vivo, in vivo, and population studies, it is expected that the generated biological and chemical construct will improve its application, establishing a knowledge platform to set and relate new biomarkers by key event relationships (KERs).

Application of AOPs to assist regulatory assessment of chemical risks – Case studies, needs and recommendations

“…For a BoE to be a reliable tool in HBM studies, it is essential to have strong confidence in the links between BoE and both chemical exposure and health outcomes. In the AOP framework, BoEs tend to coincide with MIEs/KEs between a given exposure and a given adverse outcome ( Matos Dos Santos et al, 2020 ). For BoE identification and/or validation, AOP networks, including feedback loops and modulating factors, are of particular interest, and shared KEs (nodes) are potentially more relevant as they often connect to more MIEs, KEs and/or AOs.…”

Artificial Intelligence in Drug Toxicity Prediction: Recent Advances, Challenges, and Future Perspectives

“…This can be a barrier to improving the model performance and applying these models during drug development. There is a problem to solve the “black box” model to make it more interpretable. , Therefore, the mechanistic interpretability and predictivity of the model should be balanced . The utilization of model-agnostic techniques for interpretability, such as LIME, − SHAP, and Anchors can provide an explanation for toxicity prediction.…”